IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma

Hommer A., Mohammed Ramez O., Burchert M., Kimmich F.

2010
Current Medical Research and Opinion

View publication

Therapeutic Area

Glaucoma
Categories

Clinical development

Affiliations

Sanatorium Hera, Vienna, Austria; Santen Germany, Germering, Germany; Eyecons, Pfinztal, Germany

Related Publications

Posterior Ciliary Artery Contraction by Bradykinin Receptor Subtypes and Implications for Retinal Blood Flow Dysfunction

Sharif NA, Ohia SE, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, Njie-Mbye YF

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A 3-Year Prospective Study

Akagi T, Fukuchi T, Higashide T, Udagawa S, Ohkubo S, Sugiyama K, Tanihara H, Araie M, Tomita G, Matsumoto C, Tomidokoro A, Hangai M, Kawata H, Inai M, Tanaka Y; SVF Prospector Study Group.

Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain

Canut MI, García-Feijoo J, Larrosa-Poves JM, López-López F, Pazos M, Espinoza-Cámac N, Oyagüez I, Del Rio T, Rodríguez M.

View all Glaucoma publications